Ozempic side effects that are more common in females vs. males include nausea, vomiting, dizziness, and headache. Females ...
The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...
The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. Hims & Hers Health Inc.'s stock plunged last week when the Food ...
Hims & Hers projects $725M in GLP-1 weight loss revenue for 2025, a 3.2x increase from 2024. Read why I upgrade HIMS stock ...
After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Pfizer appoints Patrizia Cavazzoni as chief medical officer, the U.S. delays the definition of 'healthy' on labels, issues ...
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
15h
Newser on MSNFDA Change on Ozempic to Shake Up the MarketThe shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...
Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...
On Friday, the US Food and Drug Administration announced drugs Wegovy and Ozempic by Novo Nordisk are no longer in shortage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results